P190 Systematic review: Gastrointestinal ultrasound scoring indices for inflammatory bowel disease
T. Goodsall1, T. Nguyen2, C. Ma2, V. Jairath2, R. Bryant3
1Department of Gastroenterology, John Hunter Hospital, Newcastle, Australia, 2Department of Clinical Trials, Robarts Clinical Trials Inc., London, Canada, 3Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, Australia
The management of inflammatory bowel disease (IBD) requires frequent monitoring and assessment of disease activity. Endoscopic assessment with biopsy remains the gold standard for disease activity. Gastrointestinal ultrasound (GIUS) is a non-invasive, accessible and affordable test used to assess and monitor IBD and has been shown to be similar to MRI for detecting disease. The aim of this study was to systematically review the literature to identify scoring indices used for GIUS measurement of disease activity in IBD and to appraise their operating characteristics.
A systematic search of Embase, Medline, Pubmed, Cochrane Central and Clinical Trials.gov from inception to July 2019 was conducted according to PRISMA guidelines. Included were all study types reporting GIUS indices used for grading activity of severity of IBD in comparison to an objective reference standard. Studies using an exclusive clinical reference standard were excluded. All study types and abstracts were considered. Study quality was assessed using the QUADAS tool.
27 eligible studies were identified investigating 1647 patients. Disease phenotype was Crohn’s disease (CD) (
The identified GIUS scoring indices demonstrate applicability to both CD and UC with good accuracy and concordance. Current evidence does not adequately address concerns about the intra- and inter-observer variability of GIUS. There is a need for robust validation of an evidence-based GIUS index before more widespread use in IBD as a surrogate for colonoscopy and in clinical trials.